Results 281 to 290 of about 145,073 (355)

Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4926-4934, June 2026.
ABSTRACT Aims Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model‐informed drug development (MIDD) to evaluate whether a 1.7‐mg maintenance dose provides comparable exposure, tolerability and BMI effects in adolescents versus adults and versus the 2.4‐mg ...
Anders Strathe   +6 more
wiley   +1 more source

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna   +10 more
wiley   +1 more source

Does Weight Loss Translate to Workplace Gains? Results of an Employment Questionnaire in Adults With Prediabetes and Overweight or Obesity

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5001-5010, June 2026.
ABSTRACT Aims Excess weight is associated with adverse health and economic disadvantage. Observational studies suggest that people with obesity are less likely to be employed and have lower income, potentially from workplace discrimination. This study examined whether weight loss achieved through a structured, dietitian‐supported program improved ...
Erica Bessell   +4 more
wiley   +1 more source

SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4602-4609, June 2026.
ABSTRACT Background Although semaglutide 2.4 mg has demonstrated significant weight loss efficacy in clinical trials, real‐world data, particularly with regard to clinically complex and underrepresented populations, remain limited. Objectives The study aims to assess the real‐world effectiveness and patient‐reported outcomes associated with the use of ...
Pierre Bel Lassen   +20 more
wiley   +1 more source

Effect of Bariatric Surgery on Osteoarthritis-Related Pain and Function: A Systematic Review and Meta-Analysis. [PDF]

open access: yesWorld J Surg
Alqahtani MMM   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy